Related by context. All words. (Click for frequent words.) 84 NYHA Class III 74 NYHA Class 73 NYHA class 72 non valvular atrial 72 preserved ejection fraction 72 ischemic cardiomyopathy 72 NYHA 71 ATACAND 71 NYHA Class IV 70 mildly symptomatic 70 NYHA functional class 70 failure NYHA 70 unstable angina pectoris 69 myocardial infarction ventricular fibrillation 69 PEGINTRON TM 69 candesartan cilexetil 69 atherothrombotic events 68 stable angina 68 systolic dysfunction 68 ARCOXIA 68 cerebrovascular events 68 NATRECOR R 68 unstable angina UA 68 cardiovascular hospitalization 68 either acutely decompensated 67 myocardial infarction stroke 67 cardiovascular hospitalizations 67 stage IIIB 67 salmeterol fluticasone 67 Erythropoietic therapies may 67 Val HeFT 67 nondiabetic patients 67 IV NSCLC 67 acute decompensated heart 67 cardiogenic shock 67 arterial thromboembolic events 67 acute myocardial infarction AMI 67 hypertension congestive heart 67 lupus nephritis 67 decompensated heart failure 67 β blockers 67 defibrillator CRT D 67 PLX STROKE targeting 66 ARIXTRA 66 thromboembolic complications 66 chronic thromboembolic pulmonary 66 HoFH 66 VIIBRYD 66 AA Amyloidosis 66 hepatorenal syndrome 66 XIENCE V demonstrated 66 morphometric vertebral fractures 66 homozygous familial hypercholesterolemia 66 PAOD 66 CRVO 66 riociguat 66 antiarrhythmic drug 66 tolvaptan 66 MACCE 66 ventricular fibrillation VF 66 left ventricular dysfunction 66 acutely decompensated congestive heart 66 cytopenias 66 onset atrial fibrillation 66 failure ADHF 66 recurrent glioblastoma multiforme 66 TNF antagonist 66 IIIa inhibitor 66 cardiac resynchronization 66 aHUS 66 paroxysmal AF 65 Infusion Reactions Severe 65 arterial thrombosis 65 Pivotal Trial 65 acute coronary syndromes ACS 65 Hypotension 65 retinal vein occlusion induced 65 myocardial infarction MI 65 eplerenone 65 systolic hypertension 65 reinfarction 65 ruboxistaurin 65 HeFH 65 severe hypercholesterolemia 65 patients undergoing percutaneous 65 severe renal insufficiency 65 somatostatin analog 65 Acute Coronary Syndromes ACS 65 PREZISTA r arm 65 unresectable HCC 65 symptomatic VTE 65 rFVIIa 65 ACTEMRA TM 65 ischemic complications 65 stage IIIb IV 65 angina pectoris 65 uncontrolled hypertension 65 diastolic heart 65 venous thromboembolic events 65 recurrent DVT 65 ejection fractions 65 induce orthostatic hypotension 65 anthracycline taxane 65 intermittent claudication 65 acute coronary syndromes 65 Diabetic Macular Edema 65 hyperphenylalaninemia HPA due 65 atrioventricular block 65 mixed dyslipidemia 65 silent ischemia 65 NATRECOR ® 65 peripheral arterial occlusive disease 65 revascularization procedures 65 mixed hyperlipidemia 64 angiotensin converting enzyme inhibitors 64 hyperkalemia 64 landmark ATHENA trial 64 antiarrhythmic drugs 64 acutely decompensated heart 64 acute decompensation 64 MKC# 64 docetaxel Taxotere ® 64 clazosentan 64 elevated triglyceride levels 64 ADP receptor antagonist 64 Viprinex TM 64 neutropenia dehydration dyspnea 64 metastatic malignant melanoma 64 Acute Decompensated Heart Failure 64 severe exacerbations 64 aldosterone antagonists 64 deep venous thromboses 64 mild vasodilator 64 non metastatic osteosarcoma 64 acute coronary syndrome 64 renal insufficiency 64 recurrent ischemia 64 chronic angina 64 pancreatic insufficiency 64 metastatic malignant 64 aspirin clopidogrel 64 dacarbazine DTIC 64 generalized edema 64 nonischemic 64 nonfatal MI 64 myocardial infarctions 64 dopaminergic therapy 64 IBS C 64 primary hypercholesterolemia 64 pericardial effusion 64 symptomatic BPH 64 overt nephropathy 64 diabetic neuropathic pain 64 HeartMate R 64 heterozygous FH 64 unstable angina 64 macular edema secondary 64 MULTAQ 64 valvular disease 64 CRT Ds 64 stable angina pectoris 64 oxypurinol 64 recurrent VTE 64 hepatic impairment 64 revascularizations 64 beta blocker therapy 64 events MACE 64 moderate renal impairment 64 Nesiritide 64 relapsed refractory multiple myeloma 64 sustained ventricular tachycardia 64 xanthine oxidase inhibitor 64 coronary revascularization 64 dasatinib Sprycel ® 64 Ranolazine 64 Atypical Hemolytic Uremic Syndrome 64 tachyarrhythmias 64 ADHF 64 occlusion CRVO 64 renal dysfunction 64 hepatic insufficiency 64 Exacerbations 64 catheter occlusion 64 peripheral sensory neuropathy 64 Acute Exacerbations 64 metastatic GIST 64 binary restenosis 64 HIV HCV coinfected 64 cardiac resynchronisation therapy 63 LV dysfunction 63 relapsing remitting MS RRMS 63 HCV RESPOND 2 63 severe neutropenia 63 DU #b 63 nonfatal stroke 63 visilizumab 63 induced macular edema 63 TAXUS Stent 63 unstable angina chest 63 recurrent NSCLC 63 oral Hycamtin 63 peritumoral brain edema 63 nonfatal myocardial infarction MI 63 refractory NSCLC 63 Toxicities 63 Chronic Heart Failure 63 ularitide 63 Brinavess 63 severe renal impairment 63 pyrexia mucositis sepsis febrile 63 invasive candidiasis 63 dosing cohort 63 certolizumab 63 intravesical therapy 63 leukemia AML 63 macrovascular events 63 macrovascular disease 63 MAGE A3 ASCI 63 Atacand 63 coronary intervention 63 resuscitated cardiac arrest 63 mcg BID 63 occlusive disease 63 Severe Primary IGFD 63 left ventricular systolic 63 refractory angina 63 Ozarelix 63 macroalbuminuria 63 hypercholesterolaemia 63 tachyarrhythmia 63 TMP SMX 63 CTEPH 63 biologic DMARD 63 dyslipidemia hypertension diabetes 63 receptor tyrosine kinase inhibitor 63 systemic embolism 63 GP IIb IIIa inhibitors 63 parecoxib 63 Syncria R 63 metformin accumulation 63 INSPIRE Trial Phase III 63 hemodynamically significant 63 XIENCE V PROMUS Stent 63 neutropenia thrombocytopenia 63 Dementia Related Psychosis 63 CYPHER Stent 63 relapsed MM 63 heFH 63 essential thrombocythemia ET 63 unresectable 63 patients undergoing CABG 63 COPD exacerbation 63 mild renal insufficiency 63 benazepril 63 opioid induced bowel dysfunction 63 MIST II 63 unresectable stage 63 Renal dysfunction 63 evaluable subjects 63 subependymal giant cell 63 CIMZIA ™ 63 UA NSTEMI 63 refractory AML 63 BENICAR HCT 63 composite endpoint 63 receiving INTRON 63 phase IIb trial 63 Eisenmenger syndrome 63 prolonged QT interval 63 NNT = 63 MGd 63 candidemia 63 procainamide 63 metformin monotherapy 63 ALN HPN 63 atypical Hemolytic Uremic Syndrome 63 LymphoStat B belimumab 63 DOXIL 63 hereditary deficiency 63 symptomatic paroxysmal AF 63 hypercholesterolemic patients 63 Postoperative complications 63 heparin induced thrombocytopenia 63 ventricular tachycardia VT 63 infarction NSTEMI 63 intravenous diuretics 63 angioplasties stents 63 receiving XGEVA 63 recombinant tissue plasminogen 63 ximelagatran 63 vWD 63 Meets Primary Endpoint 63 hypokalemia 62 IV metastatic melanoma 62 thromboembolic 62 Neovascular AMD 62 myelodysplastic syndrome MDS 62 Warfarin Coumadin 62 antiplatelet medications 62 preserved systolic 62 lipid lowering agents 62 chronic myocardial ischemia 62 Atrial fibrillation AF 62 intravenous RSD# 62 Urocortin 2 62 Bronchiectasis 62 PICSO ® 62 Soft Tissue Sarcoma 62 rosuvastatin #mg 62 PSVT 62 thromboembolic events 62 EXJADE 62 naïve HCV 62 ventricular tachyarrhythmia 62 metastatic hormone refractory 62 teriflunomide 62 ACCLAIM COPD 62 diarrhea predominant irritable 62 receiving prophylactic anticoagulation 62 systemic hypotension 62 purpura ITP 62 Aflibercept 62 post herpetic neuralgia PHN 62 olmesartan 62 posaconazole 62 metaglidasen 62 progressive dyspnea 62 primary generalized tonic 62 hematologic toxicity 62 SinuNase TM 62 deferiprone 62 minimally symptomatic 62 underwent CABG 62 chronic immune thrombocytopenic 62 terlipressin 62 Bucindolol 62 REMICADE ® 62 Acute Bacterial Sinusitis ABS 62 bronchial hyperresponsiveness 62 AVAPRO 62 irregular quivering 62 carotid stenosis 62 renal impairment 62 Pivotal Phase III 62 adverse cytogenetics 62 Hycamtin ® 62 CYPHER ® 62 6R BH4 62 thrombolytic agent 62 aortic valve stenosis 62 mcg kg REBETOL 62 angina chest 62 atherogenic dyslipidemia 62 cell lymphoma CTCL 62 interstitial pneumonitis 62 STRIDE PD 62 atherothrombotic disease 62 CIMZIA TM certolizumab pegol 62 PEGylated interferon beta 1a 62 revascularisation 62 active comparator 62 FluCAM arm 62 leukopenia 62 arsenic trioxide injection 62 haematologic 62 ribavirin therapy 62 Serious adverse reactions 62 angiotensin converting enzyme inhibitor 62 antiplatelet agent 62 venlafaxine Effexor 62 Phase #b/#a clinical 62 Patients Treated With 62 anticlotting drugs 62 Navelbine ® 62 interferon gamma 1b 62 chronic metabolic acidosis 62 MYDICAR 62 Percutaneous Transluminal Coronary Angioplasty 62 rheumatoid arthritis psoriatic arthritis 62 angina myocardial infarction 62 unfractionated heparin UFH 62 fluvastatin 62 non splenectomized 62 leucopenia 62 angiotensin receptor blocker ARB 62 5-FU/LV 62 sorafenib Nexavar 62 treat atrial flutter 62 Carvedilol 62 ZOLINZA 62 erlotinib Tarceva ® 62 TEAEs 62 Amrubicin 62 retinal vein occlusion 62 colesevelam HCl 62 occlusion PAO 62 transaminase elevations 62 vaso occlusive crisis 62 underwent resection 62 metformin sulfonylurea 62 LVSD 62 ACTOplus met 62 TAXUS Express Stent 62 chronic HCV infection 62 INCB# [003] 62 HBeAg negative 62 Tarceva TM 62 debilitating complication 62 proliferative retinopathy 62 oral antidiabetic medication 62 systemic lupus erythematosus 62 cutaneous T 62 thiazide diuretic 62 Phase 2a Clinical Trial 62 OHR/AVR# 62 Pivotal Phase 62 kidney urologic 62 acute GvHD 62 pulmonary exacerbation 62 TAXUS p value 62 hyperplasia BPH 62 Ribavirin causes 62 brivaracetam 62 acute myocardial infarctions 62 functional mitral regurgitation 62 Percutaneous Coronary Intervention 62 relapsing multiple sclerosis 62 stroke transient ischemic 62 TAXUS Element Stent System 62 Phase 2b Trial 62 Sezary syndrome 62 comparator arm 62 bone marrow reticulin deposition 62 oral anticoagulant 62 paclitaxel eluting stents 62 uremic pruritus 62 concomitant medications 62 coronary revascularization procedures 62 onset diabetes mellitus 62 Fibrillex TM 62 ipsilateral stroke 62 IIb clinical trial 62 Candesartan 62 chronic GVHD 62 myelodysplastic myeloproliferative diseases 62 patientswith 62 eosinophilic asthma 62 benign prostatic hypertrophy BPH 62 ß blockers 62 psoriatic arthritis PsA 62 reduce serum phosphate 62 angiographic outcomes 62 VAPRISOL 62 BARACLUDE ® 62 thetreatment 62 glycated hemoglobin levels 62 briakinumab 62 MADIT II 62 acarbose 62 platelet inhibitor 62 arthritis PsA 62 lopinavir r arm 62 AGGRASTAT ® tirofiban hydrochloride 62 complement inhibitor eculizumab 62 Neulasta R 61 sodium glucose cotransporter 61 repeat revascularization 61 dextromethorphan quinidine 61 Cutaneous T 61 micafungin 61 antihypertensive agents 61 tumor lysis syndrome 61 rolofylline 61 de novo lesions 61 nonalcoholic steatohepatitis 61 Acute coronary syndromes 61 milrinone 61 pulmonary exacerbations 61 multicenter Phase III 61 AGILECT R 61 prednisone prednisolone 61 hypertension diabetes mellitus 61 retinopathy nephropathy 61 hepatic failure 61 risperidone Risperdal 61 MKC# MT 61 undergoing elective percutaneous 61 aspirin heparin 61 pediatric Crohn disease 61 thyrotoxicosis 61 brand ciclesonide HFA 61 Non inferiority 61 calcineurin inhibitors 61 ACE inhibitor ramipril 61 anthracycline containing 61 Azilect ® 61 dalteparin 61 nadolol 61 bucindolol 61 evaluating CK # 61 Initiate Phase 61 systemic immunosuppressive drugs 61 ribavirin RBV 61 PRADAXA 61 rizatriptan 61 mg BID dose 61 Pulmonary hypertension 61 nicardipine 61 cardiac dysfunction 61 Tambocor 61 hypophosphatemia 61 REMINYL ® 61 R lenalidomide 61 OMNARIS HFA 61 Severe Sepsis 61 AEGR 61 azacitidine 61 BENICAR 61 refractory chronic lymphocytic 61 valvular heart disease 61 resynchronization therapy 61 anaphylactoid reactions 61 taxane resistant 61 Acute Coronary Syndrome 61 periprocedural 61 CHD CVD 61 T2DM 61 Phase 2b Clinical Trial 61 Kepivance 61 variant angina 61 chronic idiopathic thrombocytopenic purpura 61 CTAP# Capsules 61 Tolvaptan 61 acutely decompensated 61 Myocardial Infarction Study 61 delta gamma agonist 61 SJIA 61 invasive aspergillosis 61 Pivotal Clinical Trial 61 pulmonary arterial hypertension PAH 61 Unstable Angina 61 sunitinib malate 61 CLL SLL 61 HBeAg negative patients 61 Lupus nephritis 61 enalapril 61 hypokalemia hypomagnesemia 61 Implantable cardioverter defibrillators 61 hyperoxaluria 61 secondary hyperparathyroidism 61 Idiopathic Pulmonary Fibrosis IPF 61 hypercalcemia 61 rosuvastatin Crestor 61 histologically confirmed 61 cardio renal 61 extrapyramidal symptoms 61 recurrent malignant glioma 61 neovascular 61 IV tPA 61 severe malignant osteopetrosis 61 ancrod 61 acute STEMI 61 Prospective Randomized 61 oral vancomycin 61 elotuzumab 61 acute humoral rejection 61 Completes Enrollment 61 interferon alpha IFN 61 cerebrovascular accident 61 Achieves Primary Endpoint 61 receiving golimumab 61 anemia hemoglobin 61 superficial bladder cancer 61 necrotizing pancreatitis 61 paroxysmal atrial fibrillation 61 unresectable tumors 61 ACUITY trial 61 Relapsing Remitting Multiple Sclerosis 61 HF hospitalization 61 beclomethasone dipropionate 61 left ventricular hypertrophy 61 electrolyte abnormalities 61 secondary efficacy endpoint 61 oral FTY# 61 ® lenalidomide 61 renal flares 61 humanized interleukin 6 61 MERLIN TIMI 61 Pegloticase 61 artery stenosis 61 unfavorable cytogenetics 61 VT VF 61 juvenile idiopathic arthritis 61 Thal Dex 61 severe oral mucositis 61 vapreotide acetate 61 biliary tract cancer 61 multivessel disease 61 non cirrhotic portal 61 Left ventricular hypertrophy 61 recurrent glioma 61 AGGRASTAT R tirofiban hydrochloride 61 Myelodysplastic Syndrome MDS 61 Mg Uk 61 antiarrhythmic agents 61 Torsades de Pointes 61 lexidronam injection 61 lumiracoxib 61 Doxil ® 61 hoFH 61 TORISEL 61 Investigational Treatment 61 Stage IIB 61 anthracycline therapy 61 smoldering multiple myeloma 61 evaluating REVLIMID 61 #mg BID [001] 61 immunomodulatory therapy 61 intravenous cyclophosphamide 61 evaluating mipomersen 61 Heterozygous Familial Hypercholesterolemia 61 cardiovascular morbidity 61 Silodosin 61 hypereosinophilic syndrome 61 severe sepsis 61 INVEGA ® 61 hereditary antithrombin deficiency 61 achieved ACR# 61 Vernakalant 61 hypomagnesemia 61 PNH patients 61 colorectal adenoma 61 formerly LymphoStat B 61 chronic eosinophilic leukemia 61 thrombotic events 61 hour bronchodilation 61 FIRMAGON 61 engineered anticoagulant 61 investigational pharmacologically unique 61 rhythm disturbances 61 antithrombotic therapy 61 torsades de pointes 61 First Patient Enrolled 61 Thrombocytopenia 61 rosiglitazone maleate 61 diabetes mellitus T2DM 61 phase IIb clinical 61 metastatic castration resistant 61 Rheos System 61 LVAS 61 Non Alcoholic Steatohepatitis 61 decompensated liver disease 61 VaD 61 aplastic anemia AA 61 adjunctive placebo 61 hypercalcaemia 61 drotrecogin alfa activated 61 sitaxsentan 61 lymphoma CTCL 61 nitrofurantoin 61 ACTIQ ® 61 definite stent thrombosis 61 Coronary Artery Bypass Graft 61 TG MV 61 symptomatic ischemic 61 receiving PEGINTRON 61 Fludara ® 61 Relapsing remitting MS 61 Ramipril 61 Aceon 61 CYT# potent vascular disrupting 61 REYATAZ r arm 61 MACUGEN 61 Parnate 61 retinal vein occlusion RVO 61 4mg/kg 61 TNF antagonists 61 immune idiopathic thrombocytopenic 61 aripiprazole Abilify 61 BUPHENYL 61 Cilostazol 61 potassium sparing diuretics 61 dopamine partial agonist 61 sotalol 61 ACTOplus met XR 61 papillary renal cell carcinoma 61 PROMUS Element Stent 61 rALLy clinical trial 61 AIDS prophylaxis congestive 61 Inhalation Aerosol 61 autoantibody positive 61 GSK# [001] 61 chronic periodontitis 61 Tekamlo 61 antihypertensive therapy 61 HCV SPRINT 61 Avandia Actos 61 moderate hepatic impairment 60 exocrine pancreatic insufficiency 60 SPRYCEL ® 60 Decompensated Heart Failure 60 fatigue shortness 60 Class IIIb 60 esophageal candidiasis 60 C1 INH deficiency 60 TMS Therapy 60 coronary insufficiency 60 heavily pretreated 60 overactive bladder syndrome 60 intracerebral hemorrhage ICH 60 Aortic stenosis 60 myocardial ischemia 60 highly emetogenic 60 keloid scarring 60 Drug Eluting Stent System 60 remission induction 60 Keppra R 60 Lactic acidosis 60 serum phosphorous 60 microvascular disease 60 completely resected 60 InSync Sentry 60 lomitapide 60 Occlusive Disease 60 INTEGRILIN R 60 gefitinib Iressa 60 Tasimelteon 60 Intracerebral hemorrhage 60 serum phosphate 60 Keppra ® 60 Adjunctive 60 Congestive Heart Failure 60 systemic corticosteroid 60 hyperlipidemia hypertension 60 beta2 agonist 60 PRTX 60 Glimepiride 60 Initiates Phase II 60 salmeterol fluticasone propionate 60 nonfatal myocardial infarction 60 Pemetrexed 60 severe aortic stenosis 60 lenalidomide Revlimid R 60 aminotransferases 60 included neutropenia anemia 60 ischemia driven 60 syndrome IBS 60 clonic seizures 60 Uncontrolled hypertension 60 TAVR 60 edoxaban 60 KRAS mutations occur 60 recurrent stroke 60 tuberous sclerosis TS 60 pulmonary embolism PE 60 SHPT 60 relapsed acute myelogenous 60 acute PAO 60 dysfunction LVSD 60 Exacerbation 60 refractory CLL 60 AVONEX ® 60 metastatic renal cell carcinoma 60 acute peripheral arterial 60 antidepressants fluoxetine 60 malignant neoplasms 60 oral antidiabetic drugs 60 chlorambucil 60 pheochromocytoma 60 PROVIGIL ® 60 severe hypersensitivity reactions 60 progressive neurodegenerative disorder 60 APTIVUS r 60 PEG IFN 60 IV melanoma 60 hypocalcemia 60 metabolic alkalosis 60 acute myocardial infarction 60 macrovascular complications 60 CNS systemic embolism 60 diabetes mellitus DM 60 congestive cardiac 60 BCG refractory carcinoma 60 adult chronic ITP 60 Aclidinium 60 Fondaparinux 60 clopidogrel Plavix 60 palifermin 60 ZYVOX 60 Daclizumab 60 cangrelor 60 Cleviprex TM clevidipine 60 RELOVAIR ™ 60 cytotoxic therapy 60 diabetes dyslipidemia 60 EVIZON TM 60 Peginterferon alfa 2b 60 revascularization procedure 60 grade cervical intraepithelial 60 serum uric acid sUA 60 TELINTRA 60 Monopril 60 Renal Cell Carcinoma RCC 60 dosing cohorts 60 venous thromboembolisms 60 pioglitazone HCl 60 severe mitral regurgitation 60 Cimzia TM 60 placebo controlled Phase 60 XIENCE V vs. 60 dapagliflozin plus 60 Omacetaxine 60 Octreolin 60 Myocardial infarction 60 irbesartan 60 sertraline Zoloft 60 peginterferon alfa 2a Pegasys 60 PRISTIQ 60 Critical limb ischemia 60 metastatic RCC 60 ALGRX 60 gastrointestinal perforation 60 coronary revascularisation 60 nontraumatic 60 exocrine pancreatic insufficiency EPI 60 Gemzar ® 60 MYDICAR ® 60 hyperlipidaemia 60 MYLOTARG 60 small lymphocytic lymphoma 60 symptomatic carotid stenosis 60 symptomatic hyponatremia 60 ABC/3TC 60 q#h 60 sirolimus stent 60 cerebral vasospasm 60 candesartan 60 recurrent myocardial infarction 60 Myelofibrosis 60 inotropic therapy 60 Liprotamase 60 Lixivaptan 60 Chronic Bronchitis 60 pyelonephritis 60 familial hypercholesterolemia FH 60 corticosteroid therapy 60 recurrent wheezing 60 zonisamide SR 60 Nilotinib 60 transplantation HCT 60 MADIT CRT trial 60 fibrosis scarring 60 drug zotarolimus 60 infusional 5-FU/LV 60 renal kidney 60 Hypertensive 60 mecarbil 60 darapladib 60 dasatinib Sprycel 60 Idiopathic pulmonary fibrosis 60 mL/min/#.# m 2 60 AVELOX 60 PRIMO CABG2 60 idiopathic pulmonary fibrosis IPF 60 intracerebral hemorrhage 60 placebo controlled clinical 60 hypoventilation 60 plus gemcitabine 60 eosinophilic pneumonia 60 beta blockers ACE inhibitors 60 Chronic hepatitis C 60 PREZISTA r 60 thrombotic complications 60 #mg BID [003] 60 #mg/dL [001] 60 elevated LDL cholesterol 60 recurrent GBM 60 damage cirrhosis liver 60 headache nasopharyngitis 60 CINTREDEKIN BESUDOTOX 60 infliximab monotherapy 60 Valsartan 60 relapsed multiple myeloma 60 steroid refractory GvHD 60 bradycardia 60 relapsed SCLC 60 paroxetine Paxil 60 recurrent sinusitis 60 J Am Coll 60 noncardiovascular mortality 60 cardiac resynchronization therapy 60 FOLFOX6 chemotherapy regimen 60 CoreValve System 60 ACE Inhibitors 60 thalidomide Thalomid 60 Zenvia ™ 60 recurrent angina 60 phase IIa 60 hematologic disorders 60 chronic hepatitis cirrhosis 60 orthostatic hypotension 60 PENTASA 60 treat lupus renal 60 smoldering myeloma 60 postsurgical pain 60 Metastatic breast cancer 60 IV Busulfex 60 calcineurin inhibitor 60 atherothrombosis 60 cryptogenic stroke 60 hypoparathyroidism 60 Cypher Stent 60 diabetic kidney 60 Lupus Nephritis 60 rasagiline tablets 60 FRAGMIN 60 x ULN 60 non squamous NSCLC 60 QVAR R 60 nonsmall cell lung cancer 60 Mg Usa 60 argatroban 60 ORENCIA ® 60 pain palliation 60 torsade de pointes 60 everolimus eluting stents 60 piperacillin tazobactam 60 nilotinib Tasigna ® 60 Pegylated Liposomal Doxorubicin 60 reslizumab 60 somatostatin analogue 60 Newly Diagnosed Multiple Myeloma 60 Vaprisol 60 tirofiban 60 anticoagulant warfarin 60 lactic acidosis 60 unresectable liver cancer 60 plus dexamethasone 60 myocardial infarction 60 ADL# novel 60 dual endothelin receptor antagonist 60 salmeterol HFA MDI 60 RE LY ® 60 Epratuzumab 60 Dupuytren Disease 60 warfarin sodium 60 chronic obstructive lung 60 bisoprolol 60 del 5q MDS 60 de novo kidney transplant 60 oral hypoglycemic agent 60 EFFEXOR XR 60 Ophena TM 60 Wafer polifeprosan 60 FASLODEX 60 TBC# 60 tenecteplase 60 CIMZIA TM 60 dysglycemia 60 receiving VELCADE 60 albiglutide currently 60 arterial hypertension 60 Rheumatoid Arthritis RA 60 HYVISC R 60 Acute Myocardial Infarction 60 chronic HCV 60 AAT deficiency 60 vascular occlusive diseases 60 Acute Ischemic Stroke 60 Central Retinal Vein 60 QTc prolongation 60 R# #mg BID 60 Class IIIB IV 60 erythematosus 60 prolonged QT intervals 60 TAXUS Liberte stent 60 insulin detemir 60 Inspra 60 Fibrin Pad 60 selective modulator 60 gastrointestinal reflux 60 NSTEMI 60 Acute Coronary Syndromes 60 salmeterol inhalation powder 60 fluticasone salmeterol 60 choroidal neovascularization 60 antiarrhythmics 60 rufinamide 60 ventricular arrhythmias 60 hemorrhagic complications 60 ventricular arrhythmia 60 genitourinary GU 60 convulsive disorders 60 Initiated Phase 60 Hyperlipidemia 60 comparing XIENCE V 60 alpha interferons 60 Acute myeloid leukemia 60 sunitinib Sutent